-
1
-
-
84872065897
-
Jaks and stats in immunity, immunodeficiency, and cancer
-
O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013; 368: 161-170
-
(2013)
N Engl J Med
, vol.368
, pp. 161-170
-
-
O'Shea, J.J.1
Holland, S.M.2
Staudt, L.M.3
-
2
-
-
84863393110
-
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
-
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366: 799-807
-
(2012)
N Engl J Med
, vol.366
, pp. 799-807
-
-
Verstovsek, S.1
Mesa, R.A.2
Gotlib, J.3
Levy, R.S.4
Gupta, V.5
DiPersio, J.F.6
-
3
-
-
84857837774
-
Jak inhibition with ruxolitinib versus best available therapy for myelofibrosis
-
Harrison C, Kiladjian J-J, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366: 787-798
-
(2012)
N Engl J Med
, vol.366
, pp. 787-798
-
-
Harrison, C.1
Kiladjian, J.-J.2
Al-Ali, H.K.3
Gisslinger, H.4
Waltzman, R.5
Stalbovskaya, V.6
-
4
-
-
84859721377
-
Jak2 inhibition for the treatment of hematologic and solid malignancies
-
Harry BL, Eckhardt SG, Jimeno A. JAK2 inhibition for the treatment of hematologic and solid malignancies. Expert Opin Investig Drugs. 2012; 21: 637-655
-
(2012)
Expert Opin Investig Drugs
, vol.21
, pp. 637-655
-
-
Harry, B.L.1
Eckhardt, S.G.2
Jimeno, A.3
-
5
-
-
77949535491
-
Phase 2 study of cep-701, an orally available jak2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
-
Santos FPS, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G., et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010; 115: 1131-1136
-
(2010)
Blood
, vol.115
, pp. 1131-1136
-
-
Santos, F.P.S.1
Kantarjian, H.M.2
Jain, N.3
Manshouri, T.4
Thomas, D.A.5
Garcia-Manero, G.6
-
6
-
-
84857143671
-
Bcr-Abl uncouples canonical jak2-stat5 signaling in chronic myeloid leukemia
-
Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner K-U., et al. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol. 2012; 8: 285-293
-
(2012)
Nat Chem Biol
, vol.8
, pp. 285-293
-
-
Hantschel, O.1
Warsch, W.2
Eckelhart, E.3
Kaupe, I.4
Grebien, F.5
Wagner, K.-U.6
-
7
-
-
84875424883
-
Conditional deletion of jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: Implications for jak2 inhibition in humans
-
Park SO, Wamsley HL, Bae K, Hu Z, Li X, Choe S., et al. Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans. PLoS One. 2013; 8: e59675
-
(2013)
PLoS One
, vol.8
, pp. e59675
-
-
Park, S.O.1
Wamsley, H.L.2
Bae, K.3
Hu, Z.4
Li, X.5
Choe, S.6
-
8
-
-
79952333359
-
Safety and efficacy of tg101348, a selective jak2 inhibitor, in myelofibrosis
-
Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM., et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011; 29: 789-796
-
(2011)
J Clin Oncol
, vol.29
, pp. 789-796
-
-
Pardanani, A.1
Gotlib, J.R.2
Jamieson, C.3
Cortes, J.E.4
Talpaz, M.5
Stone, R.M.6
-
9
-
-
77950684805
-
Preclinical characterization of the selective jak1/2 inhibitor incb018424: Therapeutic implications for the treatment of myeloproliferative neoplasms
-
Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA., et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010; 115: 3109-3117
-
(2010)
Blood
, vol.115
, pp. 3109-3117
-
-
Quintás-Cardama, A.1
Vaddi, K.2
Liu, P.3
Manshouri, T.4
Li, J.5
Scherle, P.A.6
-
10
-
-
77953667590
-
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia
-
Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA., et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med. 2010; 2: 98-110
-
(2010)
EMBO Mol Med
, vol.2
, pp. 98-110
-
-
Hoelbl, A.1
Schuster, C.2
Kovacic, B.3
Zhu, B.4
Wickre, M.5
Hoelzl, M.A.6
-
11
-
-
33845239481
-
Stat3 governs distinct pathways in emergency granulopoiesis and mature neutrophils
-
Panopoulos AD, Zhang L, Snow JW, Jones DM, Smith AM, El Kasmi KC., et al. STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. Blood. 2006; 108: 3682-3690
-
(2006)
Blood
, vol.108
, pp. 3682-3690
-
-
Panopoulos, A.D.1
Zhang, L.2
Snow, J.W.3
Jones, D.M.4
Smith, A.M.5
El Kasmi, K.C.6
-
12
-
-
84918579424
-
Mutation of stat1/3 binding sites in gp130(fxxq) knock-in mice does not alter hematopoietic stem cell repopulation or self-renewal potential
-
Wang Z, Kang Z, Zhang Y, Tse W, Bunting KD. Mutation of STAT1/3 binding sites in gp130(FXXQ) knock-in mice does not alter hematopoietic stem cell repopulation or self-renewal potential. Am J Stem Cells. 2012; 1: 146-153
-
(2012)
Am J Stem Cells
, vol.1
, pp. 146-153
-
-
Wang, Z.1
Kang, Z.2
Zhang, Y.3
Tse, W.4
Bunting, K.D.5
-
13
-
-
84865735256
-
Heterodimeric jak-stat activation as a mechanism of persistence to jak2 inhibitor therapy
-
Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T., et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012; 489: 155-159
-
(2012)
Nature
, vol.489
, pp. 155-159
-
-
Koppikar, P.1
Bhagwat, N.2
Kilpivaara, O.3
Manshouri, T.4
Adli, M.5
Hricik, T.6
-
14
-
-
84897020107
-
Important scaffold function of the janus kinase 2 uncovered by a novel mouse model harboring a jak2 activation loop mutation
-
Keil E, Finkenstädt D, Wufka C, Trilling M, Liebfried P, Strobl B., et al. Important scaffold function of the Janus kinase 2 uncovered by a novel mouse model harboring a Jak2 activation loop mutation. Blood. 2013; 123: 520-529
-
(2013)
Blood
, vol.123
, pp. 520-529
-
-
Keil, E.1
Finkenstädt, D.2
Wufka, C.3
Trilling, M.4
Liebfried, P.5
Strobl, B.6
-
15
-
-
70349975711
-
Jak2 phosphorylates histone h3y41 and excludes hp1alpha from chromatin
-
Dawson MA, Bannister AJ, Göttgens B, Foster SD, Bartke T, Green AR., et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009; 461: 819-822
-
(2009)
Nature
, vol.461
, pp. 819-822
-
-
Dawson, M.A.1
Bannister, A.J.2
Göttgens, B.3
Foster, S.D.4
Bartke, T.5
Green, A.R.6
|